West Cancer Center

MOLECULARLY TARGETED: FGFR-mutant or fusions: FGFR inhibitor: FIGHT-207

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

VIEW TRIAL ON CLINICALTRIALS.GOV

Malignancy

Solid Tumors: Breast, Lung (NSCLC), Colon, Prostate, Bladder, Kidney, Esophagus, Stomach (Gastric), Liver (HCC), Cervical, Endometrial, Ovarian, Skin, Head and Neck (SCCHN), Bladder, Kidney (renal cell), Pancreatic, Rectal, Brain (GBM, glioblastoma)

Stage

Stage 4

Phase

Phase 2

Status

Open to Enrollment

Line Of Therapy

Following all effecive therapy (late line)

Investigational Agent

Pemigatinib

Drug Class

FGFR inhibitor

PI

Dan Vaena, MD

Sponsor

Incyte Corporation

Path

FGFR 1,2,3 mutated or FGFR 1,2,3 fusion/translocation

Key Eligibility Criteria Details

Metastatic or surgically unresectable solid tumor
Measurable disease
Documentation of an FGFR1-3 gene mutation or translocation
At least 1 prior line of therapy with progression
No other therapy available likely to provide clinical benefit
ECOG PS 0-2
No other FGFR inhibitors within last 6 months
No clinically significant corneal or retinal disorder
No untreated CNS disease (except primary brain cancer)
No additional malignancy at current time requiring active treatment
No history of calcium or phosphate disorder or systemic mineral imbalance
No clinically significant cardiac disease
No active HBV/HCV
No known HIV

MOLECULARLY TARGETED: Metastatic; Solid Tumors: HER2mt or ERBB4mt: SUMMIT

An open-label, multicenter, multinational, phase 2 study exploring the efficacy and safety of neratinib therapy in patients with solid tumors with activating HER2, HER3 or EGFR mutations or with EGFR gene amplification

VIEW TRIAL ON CLINICALTRIALS.GOV

Malignancy

Bladder, Breast, Brain (GBM), Head and Neck, Prostate, Kidney (Renal Cell), Melanoma, Ovarian, Endometrial (Uterine), Cervical, Gastric, Pancreatic, Hepatocellular (HCC), Esophageal, lymphoma, sarcoma

Stage

Stage 4

Phase

Phase 2

Status

Open to Enrollment

Line Of Therapy

Any (provided no curative therapy available)

Investigational Agent

Neratinib

Drug Class

pan-HER TKI

PI

Lee Schwartzberg, MD

Sponsor

Puma Biotechnologies

Path

HER2 (ERBB2) mutation or HER4 (ERBB4 mutation), or EGFR ex. 18 mutated lung cancer

Key Eligibility Criteria Details

Histologically confirmed cancer for which no curative therapy exists
Documented HER2 (ERBB2) or HER4 (ERBB4) mutation in any malignancy or EGFR ex 18 mutations in lung cancer.
- Currently CLOSED cohorts include: HER2mt lung, colorectal, and biliary
At least one measurable or evaluable lesion
LVEF >/=50%
ECOG PS 0-2
No prior treatment with ERBB2 (HER2) directed TKIs (eg lapatinib, afatinib, neratinib)
No symptomatic or unstable brain mets (stable are allowed)
No cumulative prior anthracycline dose >450mg/m2 doxorubicin or equivalent
No uncontrolled cardiac disease
No chronic diarrheal disorder

ADVANCED SOLID TUMORS: PHASE 1: ENDOMETRIAL, OVARIAN, Or PVRL2: CPG-03-101

A Phase 1/2 Study Evaluating the Safety, Tolerability and Preliminary Antitumor Activity of COM701 in Combination With BMS-986207 (Anti-TIGIT Antibody) and Nivolumab in Subjects With Advanced Solid Tumors.

VIEW TRIAL ON CLINICALTRIALS.GOV

Malignancy

Endometrial, Ovarian, Breast, Lung, Colon, Prostate, Gastric, Esophageal, Cervical, Melanoma, Skin, Pancreas, Pancreatic, Sarcoma, Head and Neck (HNPCC), NSCLC, SCLC, Kidney, Bladder, RCC, Prostate

Stage

Stage 4

Phase

Phase 1

Status

Open to Enrollment

Line Of Therapy

Late line (post standard therapy)

Investigational Agent

COM-701, BMS-986207, nivolumab

Drug Class

PVRIG antagonist, anti-TIGIT Ab, PD-1 antibody

PI

Dan Vaena, MD

Sponsor

Compugen, Ltd

Path

PVRL2 high (only for basket cohort)

Key Eligibility Criteria Details

Histologically or cytologically confirmed, locally advanced or metastatic solid malignancy and has exhausted all available standard therapy or not a candidate for standard therapy
ECOG PS 0-1
Prior therapy with immune therapy are eligible (except in ovarian cohort)
In Expansion cohorts patients must either have
- Advanced epithelial cancer of the ovary, fallopian tube, or peritoneum
- Advanced MSS endometrial cancer
- A different malignancy that has high expression of PVRL2
No active autoimmune disease
No interstitial lung disease
No active CNS metastases
In ovaran cohort, no prior immunotherapy
No prior therapy with PVRIG inhibitor or anti-TIGIT antibody

ADVANCED SOLID TUMORS: PHASE 1: OBI-888

A Phase I/II, Open-Label, Dose Escalation and Cohort Expansion Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors.

VIEW TRIAL ON CLINICALTRIALS.GOV

Malignancy

Colon, Ovarian, Gastric, Pancreatic, Endometrial, lung, prostate, breast

Stage

Stage 4

Phase

Phase 1

Status

Open to Enrollment

Line Of Therapy

Late line

Investigational Agent

OBI-888

Drug Class

Anti-globo-H antibody

PI

Axel Grothey, MD

Sponsor

OBI Pharma

Path

Globo-H overexpression

Key Eligibility Criteria Details

Histologically or cytologically confirmed patients with advanced or metastatic solid tumors
Measurable disease
Must have been treated with all estrablished standard-of-care therapy or determined by the physician that such established therapy is not sufficiently efficacious, or patients have declined to receive standard of care therapy
ECOG PS 0-1
Must have Globo-H overexpression as measured by central lab
No known active autoimmune or inflammatory disease
Not receiving systemic steroids of >10mg prednisone per day or equivalent

ADVANCED SOLID TUMORS: SCLC, GEJ, PDAC, Endometrial: PEN-866-001

A Phase 1/2a, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of PEN-866 in Patients With Advanced Solid Malignancies

VIEW TRIAL ON CLINICALTRIALS.GOV

Malignancy

Anal cancer, Pancreatic cancer, PDAC, Cervix, cervical cancer, Gastric cancer, Gastroesophageal cancer, SCLC, Small cell lung cancer, penile, vulvar

Stage

Stage 4

Phase

Phase 1

Status

Open to Enrollment

Line Of Therapy

2nd or later

Investigational Agent

PEN-866

Drug Class

HSP-90 inhibitor

PI

Dan Vaena, MD

Sponsor

Tarveda Therapeutics

Path

adenocarcinoma or squamous cell carcinoma

Key Eligibility Criteria Details

One of the following malignancies
- Small cell lung cancer: locally recurrent or metastatic SCLC whose disease has progressed after at least 1 prior line of chemo
- Gastric or GEJ adenoCA: Disease that has progressed after at least 1 prior line of chemo
- SCC of genitalia (anus, cervix, vulva, or penis): disease that has progressed after at least 1 prior line (adjuvant counts as prior line)
- Pancreatic CA: Disease that has progressed after at least 1 line of prior therapy (adjuvant tx counts as a line if recurrence is within 6 months)
- Endometrial CA: Disease that has progressed after at least 1 line of prior therapy (adjuvant tx counts as a line if recurrence is within 6 months)
ECOG PS 0-1
Measurable disease
No prior topoisomerase I inhibitor
No symptomatic CNS involvement
No known HIV/HBV/HCV

Regional One & West Partner at Midtown-Memphis Location

Clinical Trials